Tag - RGNX

Developments

REGENXBIO completes dosing in study of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has completed dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy (DMD). According to REGENXBIO, this milestone positions the...

June 24, 2026

Developments

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has announced new positive interim data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202—a potential best-in-class therapy for Duchenne muscular dystrophy (DMD). Trial investigator Carolina...

March 11, 2026

Tag - RGNX

REGENXBIO completes dosing in study of RGX-202 in DMD

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

Subscribe